Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

NEXT STORY
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
PREV STORY
Global Biohacking Market Forecasts and Outlook 2021-2028: Forensics Laboratories Segment Recorded Revenue Share of 28% in 2020, with High Product Adoption for Monitoring Patient Health Conditions
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec

author_avatar
NASDAQ Market News

Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a ...

author_avatar
NASDAQ Market News

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

author_avatar
NASDAQ Market News